As shown in Number 6, TM2 and TM4 are partially mixed up in formation from the antagonist-binding site also. M5 receptors. In parallel using the
Structure-Based Design of mTORC1 Inhibitors in Cancer Therapy
mTORC1 inhibitor
mTORC1 inhibitor
As shown in Number 6, TM2 and TM4 are partially mixed up in formation from the antagonist-binding site also. M5 receptors. In parallel using the